Autor: "Levis, MJ" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Autorzy:: Sanber K; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ye K; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tsai HL; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Newman M; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA.
Webster JA; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Gojo I; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ghiaur G; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Prince GT; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Gondek LP; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Smith BD; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Levis MJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
DeZern AE; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ambinder AJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Dalton WB; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2023 Apr; Vol. 64 (4), pp. 846-855. Date of Electronic Publication: 2023 Feb 06.
Typ publikacji:: Journal Article
MeSH Terms:: Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/genetics
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Retrospective Studies ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Sulfonamides ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Autorzy:: Karantanos T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Tsai HL; Division of Biostatistics and Bioinformatics, Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Gondek LP; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
DeZern AE; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ghiaur G; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Dalton WB; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Gojo I; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Prince GT; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Webster J; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Ambinder A; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Smith BD; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Levis MJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Varadhan R; Division of Biostatistics and Bioinformatics, Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Jones RJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1942-1948. Date of Electronic Publication: 2022 Apr 04.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Myelodysplastic-Myeloproliferative Diseases*/diagnosis
Myelodysplastic-Myeloproliferative Diseases*/drug therapy
Myelodysplastic-Myeloproliferative Diseases*/genetics
Neoplasms*
Core Binding Factor Alpha 2 Subunit/genetics ; Genomics ; Humans ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Autorzy:: Altman JK; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Perl AE; Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Hill JE; Astellas Pharma US, Inc., Northbrook, IL, USA.
Rosales M; Astellas Pharma US, Inc., Northbrook, IL, USA.
Bahceci E; Astellas Pharma US, Inc., Northbrook, IL, USA.
Levis MJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2021 Feb; Vol. 10 (3), pp. 797-805. Date of Electronic Publication: 2020 Dec 19.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Mutation*
Aniline Compounds/*therapeutic use
Drug Resistance, Neoplasm/*genetics
Leukemia, Myeloid, Acute/*mortality
Pyrazines/*therapeutic use
fms-Like Tyrosine Kinase 3/*genetics
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Survival Rate ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore.
Autorzy:: Li AY; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Kashanian SM; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Hambley BC; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Zacholski K; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Baer MR; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Duong VH; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
El Chaer F; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Holtzman NG; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Norsworthy KJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Levis MJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Smith BD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Kamangar F; Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.
Ghiaur G; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Emadi A; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2020 Nov; Vol. 61 (11), pp. 2743-2747. Date of Electronic Publication: 2020 Jun 14.
Typ publikacji:: Letter; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Leukemia, Promyelocytic, Acute*/diagnosis
Leukemia, Promyelocytic, Acute*/epidemiology
Leukemia, Promyelocytic, Acute*/therapy
Adult ; Baltimore/epidemiology ; Humans ; Incidence ; Tretinoin

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Clinical implications of molecular markers in acute myeloid leukemia.
Autorzy:: Kayser S; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Levis MJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Pokaż więcej
Źródło:: European journal of haematology [Eur J Haematol] 2019 Jan; Vol. 102 (1), pp. 20-35. Date of Electronic Publication: 2018 Oct 23.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Biomarkers, Tumor*
Leukemia, Myeloid, Acute/*genetics
CCAAT-Binding Factor/genetics ; CCAAT-Binding Factor/metabolism ; Genetic Predisposition to Disease ; Genetic Variation ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/genetics ; Leukemia, Promyelocytic, Acute/therapy ; Mutation ; Oncogene Proteins, Fusion ; Translocation, Genetic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
Autorzy:: McCurdy SR; a Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Levis MJ; a Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore , MD , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2018 Sep; Vol. 59 (9), pp. 2021-2039. Date of Electronic Publication: 2017 Nov 02.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Mutation*
Genetic Predisposition to Disease/*genetics
Leukemia, Myeloid/*genetics
Leukemia, Myeloid/*therapy
Acute Disease ; Humans ; Leukemia, Myeloid/pathology ; Neoplasm Recurrence, Local ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Prognosis ; Risk Factors ; Survival Analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Autorzy:: Goswami M; Myeloid Malignancies Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Hensel N; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Smith BD; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Prince GT; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Qin L; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Levitsky HI; 1] Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Cancer Immunology Experimental Medicine, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland.
Strickland SA; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jagasia M; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Savani BN; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Fraser JW; Center for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sadrzadeh H; Center for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rajkhowa T; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ito S; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jain NA; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Battiwalla M; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Fathi AT; Center for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Levis MJ; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Barrett AJ; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Hourigan CS; Myeloid Malignancies Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.; Pokaż więcej
Źródło:: Leukemia [Leukemia] 2014 May; Vol. 28 (5), pp. 1167-70. Date of Electronic Publication: 2014 Jan 10.
Typ publikacji:: Letter; Research Support, N.I.H., Intramural
MeSH Terms:: Immunotherapy*
Leukemia, Myeloid, Acute/*metabolism
Humans